3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
21
Brain Neoplasms
15
Central Nervous System Neoplasms
14
Astrocytoma
9
Glioma
7
Oligodendroglioma
5
Medulloblastoma
4
Neoplasms
3
Lymphoma
3
Gliosarcoma
3
Recurrence
2
Melanoma
2
Lymphoma, AIDS-Related
2
Leukemia, Myeloid, Acute
2
Uveal Melanoma
1
Spinal Cord Neoplasms
1
Solid Tumor
1
Optic Nerve Glioma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors
1
Lung Neoplasms
1
Intraocular Lymphoma
1
Familial ependymoma
1
Ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Cognition Disorders
1
Carcinoma, Non-Small-Cell Lung
1
Camurati-Engelmann Syndrome
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Vincristine
2
Oncolytic Virotherapy
2
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Valproic Acid
1
Radiotherapy
1
Radiation
1
Maintenance Chemotherapy
1
Lomustine
1
Interferon-gamma
1
Immunotherapy
1
Etoposide
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Antibodies, Monoclonal
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neuroectodermal Tumors
×
Lomustine
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled